Status:
COMPLETED
Can DFN-15 Terminate Migraine With Allodynia?
Lead Sponsor:
Hartford Hospital
Collaborating Sponsors:
Rami Burstein, PhD, Beth Israel Deaconess Medical Center
Dr. Reddy's Laboratories Limited
Conditions:
Migraine With Aura
Migraine Without Aura
Eligibility:
All Genders
18-64 years
Phase:
PHASE2
Brief Summary
The majority of migraineurs seeking secondary or tertiary medical care develop cutaneous allodynia during the course of migraine, a sensory abnormality mediated by sensitization of central trigeminova...
Eligibility Criteria
Inclusion
- History of migraine with or without aura for at least 3 years, based on the International Classification of Headache disorders
- Two or more migraine attacks per month on average during the year prior to enrollment
- Ability to give written consent to enrollment
Exclusion
- Fifteen or more headache days per month, on average
- Aspirin or NSAID induced asthma or allergy
- Sulfa allergy
- Any woman who is pregnant or lactacting
- History of any of the following: Coronary artery bypass surgery, heart attack, angina, stroke, serious gastrointestinal bleeding, peptic ulcer disease, and/or chronic kidney disease
- Medical Conditions requiring the use of diuretics or daily anticoagulants
- Severe uncontrolled medical problems or medications that may influence measurements
Key Trial Info
Start Date :
May 9 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 12 2019
Estimated Enrollment :
51 Patients enrolled
Trial Details
Trial ID
NCT03472378
Start Date
May 9 2018
End Date
April 12 2019
Last Update
April 16 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hartford HealthCare Headache Center
West Hartford, Connecticut, United States, 06107